BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21805378)

  • 1. DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy.
    Li D; Zhou Q; Liu Y; Yang Y; Li Q
    Med Oncol; 2012 Sep; 29(3):1622-8. PubMed ID: 21805378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
    Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
    J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
    Xu C; Wang X; Zhang Y; Li L
    Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The XRCC1 and TP53 gene polymorphisms are associated with advanced-stage disease and early distant metastasis at diagnosis in non-small cell lung cancer.
    Karaağaç M; Geredeli Ç; Yıldırım MS; Altınok T; Dede İ; İnal A; Zamani AG; Kaya B; Demirkazık A; Artaç M
    J Cancer Res Ther; 2023; 19(5):1248-1254. PubMed ID: 37787291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
    Ai Zheng; 2005 Dec; 24(12):1510-3. PubMed ID: 16351803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer.
    Du Y; Su T; Zhao L; Tan X; Chang W; Zhang H; Cao G
    PLoS One; 2014; 9(6):e99843. PubMed ID: 24933103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.
    Yin Z; Zhou B; He Q; Li M; Guan P; Li X; Cui Z; Xue X; Su M; Ma R; Bai W; Xia S; Jiang Y; Xu S; Lv Y; Li X
    BMC Cancer; 2009 Dec; 9():439. PubMed ID: 20003463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer.
    Zienolddiny S; Campa D; Lind H; Ryberg D; Skaug V; Stangeland L; Phillips DH; Canzian F; Haugen A
    Carcinogenesis; 2006 Mar; 27(3):560-7. PubMed ID: 16195237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Yuan P; Liu L; Wu C; Zhong R; Yu D; Wu J; Xu Y; Nie S; Miao X; Sun Y; Xu B; Lin D
    Cancer Biol Ther; 2010 Nov; 10(9):854-9. PubMed ID: 20814250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer].
    Wang ZH; Miao XP; Tan W; Zhang XR; Xu BH; Lin DX
    Ai Zheng; 2004 Aug; 23(8):865-8. PubMed ID: 15301704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genetic variations in DNA repair genes ERCC2 and XRCC1 were associated with the overall survival of advanced non-small-cell lung cancer patients.
    Wang S; Wang J; Bai Y; Wang Q; Liu L; Zhang K; Hong X; Deng Q; Zhang X; He M; Wu T; Xu P; Guo H
    Cancer Med; 2016 Sep; 5(9):2332-42. PubMed ID: 27465648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
    Lee SY; Kang HG; Yoo SS; Kang YR; Choi YY; Lee WK; Choi JE; Jeon HS; Shin KM; Oh IJ; Kim KS; Lee J; Cha SI; Kim CH; Kim YC; Park JY
    Lung Cancer; 2013 Nov; 82(2):330-9. PubMed ID: 23973201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
    Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MŸ
    Pharmacol Res; 2016 Sep; 111():877-884. PubMed ID: 27498158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
    Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
    Yao CY; Huang XE; Li C; Shen HB; Shi MQ; Feng JF; Pan LX; Tang JH
    Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.